Developer docs
API playgroundTry for free, no card

Search company profiles

Healx

Full company profile

uuid00004il

Namestring
Healx
Legal namestring
Healx Ltd.
Websiteurl
healx.ai
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Healx is a Cambridge, UK-based rare disease biotechnology company founded in 2014 that applies generative AI and knowledge-graph-based drug discovery to identify repurposed and combination therapies for indications lacking approved treatments. The company's core technology is the Healnet platform, which integrates 100M+ high-confidence drug-disease relationships and 1B+ extracted entities drawn from biomedical literature and multi-omics datasets, enabling parallel prioritization of candidate molecules for rare disease programs. Healx operates a portfolio of clinical and preclinical assets: HLX-1502 (Phase 2, Neurofibromatosis Type 1, FDA Fast Track designated), HLX-4310 (IND cleared, osteosarcoma), HLX-0206 (Fragile X Syndrome), HLX-0553 (Angelman Syndrome), plus undisclosed early-stage programs in NF1, oncology, and spinal cord injury.

The company's go-to-market is structured around enterprise partnerships rather than product sales. Healx monetizes through co-development and licensing arrangements with pharmaceutical companies (Sanofi, Boehringer Ingelheim, Ono Pharmaceutical, GW Pharma), milestone-based agreements, and the Rare Treatment Accelerator program that supplies AI-enabled drug discovery and clinical expertise to patient advocacy groups, academics, and early-stage biotechs (often at no cost to the partner). Patient advocacy organizations — including FRAXA, Children's Tumor Foundation, FAST, PKD Charity, and Muscular Dystrophy UK — serve a dual role as scientific collaborators and community-engagement channels. The company has raised over $100M cumulatively across funding rounds led by Atomico, Balderton Capital, and Amadeus Capital Partners, with strategic backing from AstraZeneca and Intel Capital. Headcount stands at 51-100 employees, with leadership combining AI/ML expertise and senior pharma R&D pedigree (co-founder David Brown co-invented Viagra at Pfizer).

Short descriptiontext

Healx is a Cambridge-based rare disease biotech using its proprietary Healnet AI platform for drug repurposing and discovery. It serves pharmaceutical companies through licensing deals and patient advocacy groups via its Rare Treatment Accelerator, with clinical-stage assets in neurofibromatosis and oncology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, rare disease therapeutics, drug repurposing platform, biomedical knowledge graph, clinical pipeline development
Industry2 codes
PRIMARYHLACANAA
Condition-specific Digital Therapeutics (DTx)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
AI Drug Discovery
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Co-development and Licensing Deals
TypeLicensing Royalties
Description

Healx partners with pharmaceutical companies, biotech firms, and patient groups to co-develop or license treatments. Partnerships include co-development arrangements where Healx provides AI drug discovery services in exchange for development milestones and royalties.

healx.ai
2Rare Treatment Accelerator Program
TypeProfessional Services
Description

Healx provides financial resources, drug discovery and clinical expertise to selected participants to progress drug redevelopment projects toward clinical trials, typically at no cost to partners, with potential co-funding arrangements for continuing pre-clinical work.

healx.ai
3Strategic Partnerships with Pharma
TypeLicensing Royalties
Description

Partnerships with pharmaceutical companies like Sanofi and Boehringer Ingelheim for AI-driven drug discovery targeting specific disease areas, with potential milestone payments and royalties.

healx.ai
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Healx is an AI-powered rare disease biotechnology company that operates the Healnet platform, leveraging generative AI, knowledge graphs, NLP, and machine learning to identify novel drug-disease relationships and accelerate drug repurposing and combination therapy development for rare diseases. The company develops its own therapeutic pipeline (HLX-1502, HLX-4310, HLX-0206, HLX-0553) and offers co-development, licensing, and partnership arrangements to pharmaceutical companies, biotech firms, academic institutions, and patient advocacy groups.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Delivered decades-worth of drug discovery in less than two years for Fragile X Syndrome partnership with FRAXA
+2 more records
Product overview1 text field

Healx is an AI-powered biotech company that has developed a unified technology platform (Healnet) for drug discovery focused on rare diseases. The platform leverages generative AI, knowledge graphs, and machine learning to identify novel drug-disease relationships and accelerate treatment development. The company's product portfolio consists of therapeutic candidates at various clinical stages: HLX-1502 (Phase 2, Neurofibromatosis Type 1), HLX-4310 (IND cleared, Osteosarcoma), HLX-0206 (Fragile X Syndrome), and HLX-0553 (Angelman Syndrome). Additionally, Healx offers the Rare Treatment Accelerator program to partner with external researchers for drug redevelopment projects.

Product and service1 record
1Healnet AI Platform
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
1Vuja De Sciences
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-22
Description

Strategic transaction combining Healx's AI platform with Vuja De's clinical-stage osteosarcoma program. FDA has cleared IND for HLX-4310. Partnership reinforces Healx's focus on rare and pediatric oncology, with Dr. David Warshawsky joining Healx as Global Head of Metastatic Prevention.

healx.ai
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

Partnership to utilize AI-driven platforms to discover therapies for spinal cord injury (SCI). The partnership combines Healx's machine learning and drug discovery expertise with SCI Ventures' scientific insight and datasets, targeting a condition affecting over 20 million people worldwide. Backing includes Christopher & Dana Reeve Foundation, Wings for Life, Spinal Research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-13
Description

AI collaboration focused on targeting novel rare disease indications. Partnership aims to leverage artificial intelligence to accelerate the development of new treatments for rare diseases using Healx's AI drug discovery platform.

4PKD Charity
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration to apply AI to the discovery of novel treatments for rare kidney diseases including polycystic kidney disease (PKD).

healx.ai
5FAST (Foundation for Angelman Syndrome Therapeutics)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to accelerate novel treatments for Angelman Syndrome towards the clinic using Healx's AI platform and FAST's scientific expertise.

healx.ai
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Drug discovery partnership for Fragile X Syndrome. Partnership delivered decades-worth of drug discovery in less than two years, advancing multiple clinical candidates.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to progress Neurofibromatosis treatments. Foundation also providing investment to advance NF1 treatments. Simone Manso from Healx serves on CTF Board.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration to find new treatments for rare muscle-wasting diseases.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership to discover and advance treatments for chronic pancreatitis, potentially the first treatments for this condition.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership to find treatments for Friedreich's Ataxia, a rare neurodegenerative condition.

11Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development Partner
Description

AI-based drug discovery partnership for rare neurological diseases. Healx leverages its AI platform to identify new treatment approaches.

healx.ai
12Ono Pharmaceutical
Strategic tierMinorTypeStrategic or Co-development Partner
Description

AI-powered indication expansion partnership to find new uses for existing compounds.

healx.ai
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration for Barth Syndrome drug discovery research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership to develop potential new AI-derived treatments for DIPG, a rare childhood brain tumor.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration through the Sunshine Project for Phase 1/2 clinical trial of HLX-4310 in adolescent and adult patients with relapsed or refractory sarcoma, including osteosarcoma.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public AI-driven drug discovery company combining high-throughput biology with machine learning. Most direct comparable as a platform-based AI biotech pursuing multiple therapeutic programs with pharma partnerships.

TypeDirect peer
Description

AI-driven pharma company using generative AI and active learning to design novel drug candidates. Closest comparable in business model of partnering with large pharma (Sanofi, BMS) and operating an end-to-end AI drug discovery platform.

TypeDirect peer
Description

AI-driven drug discovery company combining ML with high-throughput biology for predictive modeling of disease and therapeutics. Comparable in using AI for indication discovery and partnering with pharma (Bristol-Myers Squibb, Eli Lilly).

TypeDirect peer
Description

UK-based AI drug discovery company using knowledge graphs and ML for target identification. Direct comparable in geography, technology approach (knowledge graphs), and pharma partnership model (AstraZeneca).

TypeDirect peer
Description

Computational drug discovery platform combining physics-based simulation with ML. Comparable in applying computational methods to drug discovery, with both internal pipeline and pharma software partnerships (Bristol-Myers Squibb, Bayer).

TypeDirect peer
Description

AI drug discovery company using structure-based deep learning for hit identification. Comparable as a private AI biotech pursuing pharma partnerships across multiple therapeutic areas.

TypeDirect peer
Description

AI-driven biotech using generative AI for de novo drug design with clinical-stage assets. Comparable in applying generative AI end-to-end from target discovery to clinical development with pharma partnerships.

TypeBroad incumbent
Description

Established commercial rare disease biotech with multiple approved and clinical-stage products. Comparable in therapeutic area focus (rare diseases) and partnership-based development approach, though significantly larger and more mature.

TypeBroad incumbent
Description

Large rare disease-focused biotech with multiple approved enzyme replacement and gene therapies. Comparable in deep rare disease focus and regulatory expertise, though at much greater commercial scale than Healx.

TypeBroad incumbent
Description

Major rare disease division of AstraZeneca with multiple approved rare disease therapies. Comparable as a large strategic partner (Healx's investor and partner candidate) and benchmark for what successful rare disease commercialization looks like at scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Healx

AI Drug Discoveryhealx.ai

Healx is a Cambridge-based rare disease biotech using its proprietary Healnet AI platform for drug repurposing and discovery. It serves pharmaceutical companies through licensing deals and patient advocacy groups via its Rare Treatment Accelerator, with clinical-stage assets in neurofibromatosis and oncology.

What Healx does

Healx is a Cambridge, UK-based rare disease biotechnology company founded in 2014 that applies generative AI and knowledge-graph-based drug discovery to identify repurposed and combination therapies for indications lacking approved treatments. The company's core technology is the Healnet platform, which integrates 100M+ high-confidence drug-disease relationships and 1B+ extracted entities drawn from biomedical literature and multi-omics datasets, enabling parallel prioritization of candidate molecules for rare disease programs. Healx operates a portfolio of clinical and preclinical assets: HLX-1502 (Phase 2, Neurofibromatosis Type 1, FDA Fast Track designated), HLX-4310 (IND cleared, osteosarcoma), HLX-0206 (Fragile X Syndrome), HLX-0553 (Angelman Syndrome), plus undisclosed early-stage programs in NF1, oncology, and spinal cord injury.

The company's go-to-market is structured around enterprise partnerships rather than product sales. Healx monetizes through co-development and licensing arrangements with pharmaceutical companies (Sanofi, Boehringer Ingelheim, Ono Pharmaceutical, GW Pharma), milestone-based agreements, and the Rare Treatment Accelerator program that supplies AI-enabled drug discovery and clinical expertise to patient advocacy groups, academics, and early-stage biotechs (often at no cost to the partner). Patient advocacy organizations — including FRAXA, Children's Tumor Foundation, FAST, PKD Charity, and Muscular Dystrophy UK — serve a dual role as scientific collaborators and community-engagement channels. The company has raised over $100M cumulatively across funding rounds led by Atomico, Balderton Capital, and Amadeus Capital Partners, with strategic backing from AstraZeneca and Intel Capital. Headcount stands at 51-100 employees, with leadership combining AI/ML expertise and senior pharma R&D pedigree (co-founder David Brown co-invented Viagra at Pfizer).

Healx firmographics

Firmographics
Name
Healx
Legal name
Healx Ltd.
Website
https://healx.ai
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Healx is a Cambridge-based rare disease biotech using its proprietary Healnet AI platform for drug repurposing and discovery. It serves pharmaceutical companies through licensing deals and patient advocacy groups via its Rare Treatment Accelerator, with clinical-stage assets in neurofibromatosis and oncology.
Ownership category
akta.pro rank

Healx industry classification

Industry
Product category
AI Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLACANAA
Condition-specific Digital Therapeutics (DTx)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • AI drug discovery
  • Rare disease therapeutics
  • Drug repurposing platform
  • Biomedical knowledge graph
  • Clinical pipeline development

Where Healx is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Healx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Co-development and Licensing Deals: Healx partners with pharmaceutical companies, biotech firms, and patient groups to co-develop or license treatments. Partnerships include co-development arrangements where Healx provides AI drug discovery services in exchange for development milestones and royalties.
  2. Rare Treatment Accelerator Program: Healx provides financial resources, drug discovery and clinical expertise to selected participants to progress drug redevelopment projects toward clinical trials, typically at no cost to partners, with potential co-funding arrangements for continuing pre-clinical work.
  3. Strategic Partnerships with Pharma: Partnerships with pharmaceutical companies like Sanofi and Boehringer Ingelheim for AI-driven drug discovery targeting specific disease areas, with potential milestone payments and royalties.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Healx product offering

Product offering

Core offering

Healx is an AI-powered rare disease biotechnology company that operates the Healnet platform, leveraging generative AI, knowledge graphs, NLP, and machine learning to identify novel drug-disease relationships and accelerate drug repurposing and combination therapy development for rare diseases. The company develops its own therapeutic pipeline (HLX-1502, HLX-4310, HLX-0206, HLX-0553) and offers co-development, licensing, and partnership arrangements to pharmaceutical companies, biotech firms, academic institutions, and patient advocacy groups.

Product overview

Healx is an AI-powered biotech company that has developed a unified technology platform (Healnet) for drug discovery focused on rare diseases. The platform leverages generative AI, knowledge graphs, and machine learning to identify novel drug-disease relationships and accelerate treatment development. The company's product portfolio consists of therapeutic candidates at various clinical stages: HLX-1502 (Phase 2, Neurofibromatosis Type 1), HLX-4310 (IND cleared, Osteosarcoma), HLX-0206 (Fragile X Syndrome), and HLX-0553 (Angelman Syndrome). Additionally, Healx offers the Rare Treatment Accelerator program to partner with external researchers for drug redevelopment projects.

Differentiator

Problem solved

Functional benefit

Products and services

  • Healnet AI Platform

Quantifiable outcome

  • Delivered decades-worth of drug discovery in less than two years for Fragile X Syndrome partnership with FRAXA
  • +2 more outcomes

Companies that use Healx

Customer profile

Named customers13 records

Segments4 records

Ideal customer profiles4 records

Healx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Healx partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and minor.

  • Vuja De SciencescoreStrategic or Co-development Partner · 22 September 2025Strategic transaction combining Healx's AI platform with Vuja De's clinical-stage osteosarcoma program. FDA has cleared IND for HLX-4310. Partnership reinforces Healx's focus on rare and pediatric oncology, with Dr. David Warshawsky joining Healx as Global Head of Metastatic Prevention.
  • SCI VenturescoreStrategic or Co-development Partner · 1 July 2025Partnership to utilize AI-driven platforms to discover therapies for spinal cord injury (SCI). The partnership combines Healx's machine learning and drug discovery expertise with SCI Ventures' scientific insight and datasets, targeting a condition affecting over 20 million people worldwide. Backing includes Christopher & Dana Reeve Foundation, Wings for Life, Spinal Research.
  • SanoficoreStrategic or Co-development Partner · 13 November 2024AI collaboration focused on targeting novel rare disease indications. Partnership aims to leverage artificial intelligence to accelerate the development of new treatments for rare diseases using Healx's AI drug discovery platform.
  • PKD CharitycoreStrategic or Co-development PartnerCollaboration to apply AI to the discovery of novel treatments for rare kidney diseases including polycystic kidney disease (PKD).
  • FAST (Foundation for Angelman Syndrome Therapeutics)coreStrategic or Co-development PartnerPartnership to accelerate novel treatments for Angelman Syndrome towards the clinic using Healx's AI platform and FAST's scientific expertise.
  • FRAXA Research FoundationcoreStrategic or Co-development PartnerDrug discovery partnership for Fragile X Syndrome. Partnership delivered decades-worth of drug discovery in less than two years, advancing multiple clinical candidates.
  • Children's Tumor FoundationcoreStrategic or Co-development PartnerPartnership to progress Neurofibromatosis treatments. Foundation also providing investment to advance NF1 treatments. Simone Manso from Healx serves on CTF Board.
  • Muscular Dystrophy UKminorStrategic or Co-development PartnerCollaboration to find new treatments for rare muscle-wasting diseases.
  • Mission: CureminorStrategic or Co-development PartnerPartnership to discover and advance treatments for chronic pancreatitis, potentially the first treatments for this condition.
  • Ataxia UK and FARAminorStrategic or Co-development PartnerPartnership to find treatments for Friedreich's Ataxia, a rare neurodegenerative condition.
  • Boehringer IngelheimcoreStrategic or Co-development PartnerAI-based drug discovery partnership for rare neurological diseases. Healx leverages its AI platform to identify new treatment approaches.
  • Ono PharmaceuticalminorStrategic or Co-development PartnerAI-powered indication expansion partnership to find new uses for existing compounds.
  • Boston Children's HospitalminorStrategic or Co-development PartnerCollaboration for Barth Syndrome drug discovery research.
  • Institute of Cancer Research (ICR)minorStrategic or Co-development PartnerPartnership to develop potential new AI-derived treatments for DIPG, a rare childhood brain tumor.
  • National Pediatric Cancer FoundationcoreStrategic or Co-development PartnerCollaboration through the Sunshine Project for Phase 1/2 clinical trial of HLX-4310 in adolescent and adult patients with relapsed or refractory sarcoma, including osteosarcoma.

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

Healx competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning. Most direct comparable as a platform-based AI biotech pursuing multiple therapeutic programs with pharma partnerships.
  • Exscientia: AI-driven pharma company using generative AI and active learning to design novel drug candidates. Closest comparable in business model of partnering with large pharma (Sanofi, BMS) and operating an end-to-end AI drug discovery platform.
  • Insitro: AI-driven drug discovery company combining ML with high-throughput biology for predictive modeling of disease and therapeutics. Comparable in using AI for indication discovery and partnering with pharma (Bristol-Myers Squibb, Eli Lilly).
  • BenevolentAI: UK-based AI drug discovery company using knowledge graphs and ML for target identification. Direct comparable in geography, technology approach (knowledge graphs), and pharma partnership model (AstraZeneca).
  • Schrödinger: Computational drug discovery platform combining physics-based simulation with ML. Comparable in applying computational methods to drug discovery, with both internal pipeline and pharma software partnerships (Bristol-Myers Squibb, Bayer).
  • Atomwise: AI drug discovery company using structure-based deep learning for hit identification. Comparable as a private AI biotech pursuing pharma partnerships across multiple therapeutic areas.
  • Insilico Medicine: AI-driven biotech using generative AI for de novo drug design with clinical-stage assets. Comparable in applying generative AI end-to-end from target discovery to clinical development with pharma partnerships.

Broad incumbents

  • Ultragenyx Pharmaceutical: Established commercial rare disease biotech with multiple approved and clinical-stage products. Comparable in therapeutic area focus (rare diseases) and partnership-based development approach, though significantly larger and more mature.
  • BioMarin Pharmaceutical: Large rare disease-focused biotech with multiple approved enzyme replacement and gene therapies. Comparable in deep rare disease focus and regulatory expertise, though at much greater commercial scale than Healx.
  • Alexion (AstraZeneca Rare Disease): Major rare disease division of AstraZeneca with multiple approved rare disease therapies. Comparable as a large strategic partner (Healx's investor and partner candidate) and benchmark for what successful rare disease commercialization looks like at scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Healx social profiles

Digital presence

Healx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Healx leadership team

Management profile

Number of profiles

Profiles18 records

Healx funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Healx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Healx

What does Healx do?

Healx is an AI-powered rare disease biotechnology company that operates the Healnet platform, leveraging generative AI, knowledge graphs, NLP, and machine learning to identify novel drug-disease relationships and accelerate drug repurposing and combination therapy development for rare diseases. The company develops its own therapeutic pipeline (HLX-1502, HLX-4310, HLX-0206, HLX-0553) and offers co-development, licensing, and partnership arrangements to pharmaceutical companies, biotech firms, academic institutions, and patient advocacy groups.

Is Healx a public or private company?

Healx is a private company. It is classified as venture growth investor backed and is currently operating.

When was Healx founded?

Healx was founded in 2014. It employs 51 to 100 people.

Where is Healx based?

Healx is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Healx make money?

Three revenue lines are on record. Co-development and Licensing Deals are the primary driver. The others are rare Treatment Accelerator Program and strategic Partnerships with Pharma.

Who are Healx's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Exscientia, Insitro, BenevolentAI, Schrödinger, Atomwise and Insilico Medicine. Broad incumbents are Ultragenyx Pharmaceutical, BioMarin Pharmaceutical and Alexion (AstraZeneca Rare Disease).

Does Healx have an API?

No public API is recorded for Healx.

What industry is Healx in?

Healx's product category is AI Drug Discovery. Its primary akta.pro industry code is HLACANAA, Condition-specific Digital Therapeutics (DTx), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireHealx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on OsteosarcomaHealx announced that the first patient has been dosed in a Phase 1/2 dose-escalation and dose-confirmation clinical trial evaluating HLX-4310, an investigational oral combination of a class I selective HDAC inhibitor and an mTOR inhibitor, in adolescents and adults with relapsed, refractory sarcoma, with a focus on osteosarcoma. HLX-4310 represents the first clinical proof point for Healx's broader rare oncology strategy focused on preventing metastatic recurrence, which is responsible for the vast majority of cancer-related deaths. The trial is being advanced in collaboration with the National Pediatric Cancer Foundation's Sunshine Project™ consortium of leading pediatric cancer centers.BioSpaceHealx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on OsteosarcomaHealx announced the first patient dosed in its Phase 1/2 trial of HLX-4310, an oral HDAC and mTOR inhibitor combination, for relapsed, refractory sarcoma with a focus on osteosarcoma. The trial, in collaboration with the National Pediatric Cancer Foundation's Sunshine Project, aims to evaluate safety and efficacy, including potential to reduce metastatic recurrence risk.IbtimesUK's Top 10 AI Companies Driving Innovation and Growth in 2026The UK's artificial intelligence sector has consolidated its position as Europe's leading AI hub in 2026, with over 5,800 AI companies contributing approximately £45 billion to the national economy. This article profiles 10 standout UK AI companies including Google DeepMind, Wayve, Synthesia, Stability AI, Quantexa, ElevenLabs, Isomorphic Labs, Faculty, Darktrace, and Healx, selected based on valuation, funding, technological impact, and industry influence across applications ranging from foundational research to autonomous systems, synthetic media, cybersecurity, and drug discovery. The sector continues attracting substantial venture capital investment while navigating challenges around compute resources, talent retention, and regulatory frameworks, with London, Cambridge, and other tech clusters serving as primary innovation hubs.PR NewswireRare Disease Campaign Launches NationwideMediaplanet announced the launch of its Rare Diseases awareness campaign on March 13, 2026, debuting in USA Today and online, uniting patients, researchers, healthcare leaders, and advocates to advance awareness and treatment for rare diseases affecting over 300 million people worldwide. The campaign features editorial contributions from patient advocacy organizations, medical experts, and pharmaceutical innovators including Soleno Therapeutics, Atossa Therapeutics, and Healx, as well as a cover interview with Broadway star Aaron Lazar discussing his ALS diagnosis. The initiative aims to inspire continued investment and collaboration across the healthcare landscape through patient storytelling and expert commentary.openPR.comArtificial Intelligence Biotechnology Market Next Big Thing | Major Giants Healx, Cyclica, IktosThe article discusses the artificial intelligence biotechnology market, highlighting key players such as Healx, Cyclica, and Iktos, and analyzing its segmentation, regional dominance, and growth trends through 2033. It emphasizes the increasing adoption of AI in drug discovery, genomics, and diagnostics driven by need for faster insights and personalized medicine.BioSpaceMachine Learning in Drug Discovery Market to Witness Exponential Growth: Key Players, $250M Eli Lilly Deal & Regional Insights for 2025-2034The global machine learning in drug discovery market is projected to expand significantly during 2025–2034, driven by demand for faster, more affordable drug development and rising chronic disease prevalence. North America dominated the market in 2024, while Asia Pacific is expected to grow at the fastest CAGR over the forecast period, with China, Japan, India, and South Korea investing heavily in AI-driven healthcare innovation. Recent strategic collaborations include Healx's July 2025 alliance with SCI Ventures for AI-powered paralysis therapies and XtalPi's July 2025 partnership with Pfizer to expand AI-driven drug discovery.Business Wire BlogHealx and SCI Ventures Join Forces to Uncover Cures for Paralysis with AI-Driven Drug DiscoveryHealx and SCI Ventures partnered to use AI to discover treatments for spinal cord injury, a condition affecting over 20 million people. SCI Ventures will invest in Healx to accelerate therapies, with chronic SCI care costs reaching $3-6 million per patient. The collaboration may also advance treatments for other CNS conditions like ALS and stroke.GenengnewsHealx Candidate, SpringWorks Therapy Expand NF1 Treatment OptionsHealx has dosed the first patient in a Phase II trial for HLX-1502, an AI-discovered drug targeting neurofibromatosis type 1 (NF1), while SpringWorks Therapeutics recently received FDA approval for Gomekli, the first treatment for NF1 in adults. These developments expand therapeutic options for the rare genetic disorder, with SpringWorks also advancing into advanced acquisition talks with Merck KGaA.SAGE Publications IncArtificial intelligence in drug development: reshaping the therapeutic landscapeThe article reviews how artificial intelligence is transforming pharmaceutical drug discovery by accelerating target identification, molecular design, and clinical trial predictions while reducing development costs. It highlights specific advancements by companies such as Heal-X, Deep Genomics, Insilico Medicine, and Chemistry42, whose AI-driven candidates have entered clinical trials for conditions like fragile X syndrome and idiopathic pulmonary fibrosis. Despite challenges regarding algorithm transparency and data quality, the technology is projected to significantly enhance efficiency and generate substantial economic value for the industry.Business Wire BlogHealx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platformHealx announced an agreement with Sanofi to use a Sanofi compound to identify new rare disease indications via its Healnet AI platform. Sanofi will provide data on a late-stage discontinued asset, with financial terms undisclosed. Healx will also provide AI-driven therapeutic rationale for the compound's future development.